Novo Nordisk A/S (NVO)

104.15 +0.65 (+0.63%) As of 03:46PM EDT. Market open.

Novo Nordisk A/S

Novo Allé 1
Bagsvaerd 2880
Denmark
45 44 44 88 88
https://www.novonordisk.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 49,295

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Lars Fruergaard Jorgensen	Pres, CEO & Member of Management Board	5.06M	N/A	1966
Mr. Karsten Munk Knudsen	Exec. VP, CFO & Member of the Management Board	1.87M	N/A	1971
Mr. Henrik Ehlers Wulff	Exec. VP, Head of Product Supply, Quality & IT and Member of the Management Board	1.97M	N/A	1970
Ms. Camilla Sylvest	Exec. VP, Head of Commercial Strategy & Corp. Affairs and Member of the Management Board	1.87M	N/A	1972
Ms. Monique Carter	Exec. VP, Head of People & Organisation and Member of Management Board	1.42M	N/A	1973
Mr. Maziar Mike Doustdar	Exec. VP, Head of International Operations & Member of the Management Board	N/A	N/A	1970
Mr. Douglas J. Langa	Exec. VP, Head of North America Operations & Member of Management Board	N/A	N/A	1966
Mr. Ludovic Helfgott	Exec. VP, Head of Rare Disease & Member of Management Board	N/A	N/A	1974
Dr. Martin Holst Lange	Exec. VP, Head of Devel. & Member of the Management Board	N/A	N/A	1970
Dr. Marcus Schindler Ph.D.	EVP, Head of Research & Early Devel., Chief Scientific Officer & Member of the Management Board	N/A	N/A	1966

Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Corporate governance

Novo Nordisk A/S’s ISS governance QualityScore as of 1 May 2022 is 4. The pillar scores are Audit: 3; Board: 4; Shareholder rights: 10; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.